Stéphane Huguet is an emergency care physician by training and holds an MBA from the INSEAD. He has held several management positions in pharmaceutical companies in Europe, the United States and Canada. In 2000, he created and developed two startup, one in the field of biotechnology, which was sold to a major US pharmaceutical company. The other, which marketed pharmaceutical products in France, was sold to POI. Stéphane Huguet now runs POI and its subsidiaries.
Director of Medicinal Chemistry
After a PhD in Chemistry and Physico-chemistry of compounds with a biological interest in 1996, Sophie CHASSET begins her industrial career in 1997 as a medicinal chemist in the field of the Central Nervous System at the Laboratoire Louis Lafon (bought by Cephalon). In 2007, Sophie joins Novexel as group leader in anti-infectious medicinal chemistry and project leader on antibacterial Discovery. Following Novexel acquisition by Astra Zeneca in 2010 Sophie CHASSET joins Mutabilis as Director of Antiviral Chemistry. Since the end of 2015 she is heading Mutabilis’ Medicinal Chemistry with a team of 14 chemists. Sophie CHASSET co-authored 6 publications and 14 patents or patent applications.
Biology Vice President & Scientic Director
François Moreau has over 15 years’ experience in the pharmaceutical industry. After a PhD in bio-organic chemistry in Paris, he joined Pfizer in 1998 as a group leader in enzymology/HTS in the therapeutic area of allergy and respiratory diseases. He joined MUTABILIS in 2004 and contributed to the development of new classes of antibacterials such as the FabI inhibitor FAB001. François Moreau is the co-author of 21 articles and co-inventor of nine patents, primarily in the field of the inhibition of bacterial virulence. At MUTABILIS he leads the multidisciplinary team of biochemists, microbiologists, virologists and highly qualified pharmacologists. He also supervises external studies in ADME and the toxicology of drug candidates.
Richard Benarous led the INSERM Unit 529, and the Department of Infectious Diseases of the Cochin Institute (Paris). In molecular virology, he specializes in host-virus interactions in HIV. He discovered several HIV-1 cofactors, including the LEDGF-Integrase partnership by double-hybrid screening. He was a member of the expertise jury for the Marie Curie Fellowships for the European FP6 Framework Program. He also participated in several European projects on HIV and is currently coordinator of the HIVINNOV consortium. He is the founder of three biotechnology companies: Hybrigenics, Cytomics and CellVir. Richard Benarous is the author of more than 115 international publications.
After obtaining a Master in Cell Biology and a Master 2 in Business Administration, she joined Bayer-Diagnostics in 2002 as implementation engineer. In 2004, she moved one year to Russia in a consulting firm as a project manager, responsible for market research in the health sector. Upon her return to France, Stéphane Huguet hired her to work in the Business Development of the Upharm Company, and then of PharmaOmnium. It is on this occasion that she participated in the due-diligence leading to the acquisition of MUTABILIS. Currently Administration Director, she is in charge of all non-scientific responsibilities at MUTABILIS.